

1 Continuous Bayesian Variant Interpretation

2 Accounts for Incomplete Penetrance among

3 Mendelian Cardiac Channelopathies

4 Short Title: Continuous Bayesian Penetrance Probabilities

5
6 Matthew J. O'Neill¹, Luca Sala², Isabelle Denjoy³, Yuko Wada⁴,

7 Krystian Kozek¹, Lia Crotti², Federica Dagradi², Maria-Christina Kotta², Carla Spazzolini²,

8 Antoine Leenhardt³, Joe-Elie Salem³, Asami Kashiwa⁵, Seiko Ohno⁶, Ran Tao⁷, Dan M. Roden⁸,

9 Minoru Horie⁹, Fabrice Extramiana³, Peter J. Schwartz², and Brett M. Kroncke^{4*}

10
11 1. Vanderbilt University School of Medicine, Medical Scientist Training Program, Vanderbilt
12 University, Nashville, TN

13 2. IRCCS, Istituto Auxologico Italiano, Center for Cardiac Arrhythmias of Genetic Origin and
14 Laboratory of Cardiovascular Genetics, Milano, Italy

15 3. Department of Cardiovascular Medicine, Hôpital Bichat, APHP, Université de Paris Cité,
16 Paris, France

17 4. Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART), Division of
18 Clinical Pharmacology, Department of Medicine, Vanderbilt University Medical Center,
19 Nashville, TN

20 5. Department of Cardiovascular Medicine, Kyoto University Graduate School of Medicine
21 Kyoto, Japan

22 6. Department of Bioscience and Genetics, National Cerebral and Cardiovascular Center,
23 Osaka, Japan

- 24 7. Department of Biostatistics, Vanderbilt University Medical Center, Nashville, TN
- 25 8. Vanderbilt Center for Arrhythmia Research and Therapeutics (VanCART), Departments
- 26 of Medicine, Pharmacology, and Biomedical Informatics, Vanderbilt University Medical
- 27 Center, Nashville, TN
- 28 9. Department of Cardiovascular Medicine, Shiga University of Medical Science, Shiga,
- 29 Japan

30

31 *Correspondence to Brett M. Kroncke:

32 Office 1215E Light Hall/Medical Research Building IV

33 2215 Garland Avenue

34 Nashville, TN, 37232

35 brett.m.kroncke.1@vumc.org

36 **Abstract**

37

38 **Background:** The congenital Long QT Syndrome (LQTS) and Brugada Syndrome (BrS) are
39 Mendelian autosomal dominant diseases which frequently precipitate fatal cardiac arrhythmias.
40 Incomplete penetrance is a barrier to clinical management of heterozygotes harboring variants
41 in the major implicated disease genes *KCNQ1*, *KCNH2*, and *SCN5A*. We apply and evaluate a
42 Bayesian penetrance estimation strategy that accounts for this phenomenon and evaluate
43 penetrance distributions and rationalize their structural underpinnings across four genotype-
44 phenotype pairs.

45

46 **Methods:** We generated Bayesian penetrance estimation models for *KCNQ1*-LQT1 and
47 *SCN5A*-LQT3 using variant-specific features and clinical data from the literature, international
48 arrhythmia genetic centers, and population controls. We analyzed the distribution of posterior
49 penetrance estimates across four-genotype phenotype relationships and compared continuous
50 estimates to ClinVar annotations. Posterior estimates were mapped onto protein structure.

51

52 **Results:** Bayesian models of *KCNQ1*-LQT1 and *SCN5A*-LQT3 are well-calibrated to clinical
53 observations. Variant-informed penetrance estimates of *KCNQ1*-LQT1 and *SCN5A*-LQT3 are
54 empirically equivalent to 10 and 5 heterozygote clinical phenotypes, respectively. Posterior
55 penetrance estimates were bimodal for *KCNQ1*-LQT1 and *KCNH2*-LQT2, with a higher fraction
56 of missense variants with high penetrance among *KCNQ1* variants. *SCN5A*-LQT3 and *SCN5A*-
57 BrS had comparatively more variants with predicted low penetrance. There was a wide
58 distribution of variant penetrance estimates among similar categories of ClinVar annotations.
59 Structural mapping revealed heterogeneity among 'hot spot' regions and featured high
60 penetrance estimates for *KCNQ1* variants in contact with calmodulin and the S6 domain.

61

62 **Conclusions:** Bayesian penetrance estimates provide a continuous framework for variant
63 interpretation, provide higher resolution within ‘hot spot’ domains, and facilitate prospective
64 clinical management of variant heterozygotes.

65

66 Introduction

67 Incomplete penetrance is a hallmark of the inconsistency of genetic determinism, where
68 heterozygotes harboring the same variant may manifest a continuum of the disease phenotype,
69 or none at all¹⁻³. The nuance of incomplete penetrance is frequently unaccounted for in
70 contemporary genetic methods development; probabilistic approaches may more accurately
71 account for variable genetic contributions to disease presentation. The American College of
72 Medical Genetics and Genomics (ACMG) has established criteria for adjudicating the
73 'pathogenicity' of variants, drawing to varying extents on population frequency data, segregation
74 within families, *in silico* methods, and functional data, among other sources⁴. However, this
75 categorical approach is unable to account for incomplete penetrance, especially among ClinVar-
76 annotated Pathogenic or Likely Pathogenic variants⁵.

77 Clinical management of patients affected by inherited arrhythmic syndromes is a salient
78 example of this challenge. The Long QT Syndromes Type 1-3 (LQT1-3 [MIM: 192500, 613688,
79 603830], respectively) and Brugada Syndrome (BrS [MIM 601144]) are frequently responsible
80 for Sudden Cardiac Death⁶. The most rigorously established genotype-phenotype relationships
81 are loss-of-function variants in *KCNQ1* encoding K_v7.1 (LQT1), *KCNH2* encoding K_v11.1
82 (LQT2), and *SCN5A* encoding Na_v1.5 (BrS) and gain-of-function variants in *SCN5A* (LQT3)^{7,8}.
83 These membrane proteins are responsible for orchestrating the cardiac action potential through
84 cardiomyocyte depolarization and repolarization. All four of these genotype-phenotype pairs are
85 characterized by a significant degree of incomplete penetrance⁹, which may in part be
86 accounted for by environmental risk factors as well as polygenic liability¹⁰⁻¹². The ability to
87 accurately predict variant penetrance is especially important, since medical or interventional
88 therapies are well established to lower the risk of fatal ventricular arrhythmias⁶; however, overly
89 aggressive management may conversely cause harm^{13,14}. New methods for variant
90 interpretation that capture the granularity of clinical penetrance in a probabilistic manner will
91 help facilitate the clinical management of variant heterozygotes.

92 Herein, we elaborate a framework where variant-specific features inform a continuous,
93 quantitative probability of disease manifestation (penetrance) for missense variants – in contrast
94 to the probability of ‘pathogenic’ or ‘benign’ classification^{15,16}. These prior estimates are
95 calibrated to clinically observed penetrance from the spectrum of all available variant-specific
96 feature data. Within a Bayesian framework, we apply clinical evidence from phenotyped
97 individuals from the literature, arrhythmia genetics clinical cohorts, and putative population
98 controls to these calibrated prior estimates of disease probability to yield posterior penetrance
99 estimates (Figure 1). This approach recasts nuanced variant features, previously only
100 interpretable by specialists, e.g., structural and channel biophysical properties, to a wider
101 audience as an equivalent number of clinically phenotyped heterozygotes. These estimates can
102 therefore inform clinical management in the absence of prior clinical observations of a variant, or
103 aid in interpretation of variants when few heterozygotes have been clinically phenotyped.

104 Implementing two instances of this approach, we develop penetrance models for
105 *KCNQ1-LQT1* and *SCN5A-LQT3*, incorporate data from *KCNH2-LQT2*¹⁷ and *SCN5A-BrS1*¹⁸,
106 and investigate penetrance across these four genotype-phenotype relationships. We
107 demonstrate how penetrance varies among these genotype-phenotype relationships and
108 correlate penetrance with structural features of each gene product.

109

110 **Materials and Methods**

111 All data and code used to generate and evaluate the models are available on GitHub. Results
112 are also curated in the *KCNQ1* and *SCN5A* variant browsers (see Web Resources). Detailed
113 methods are available in the Supplemental Methods.

114

115

116 **Results**

117 *Evaluation and Performance of KCNQ1 Variant Penetrance Model.* We implemented a
118 Bayesian penetrance model using all available data for the *KCNQ1*-LQT1 genotype-phenotype
119 pair (Figure 1)^{17,18}. We curated >2,000 manuscripts from the literature, and in combination with
120 phenotyped heterozygotes from international arrhythmia clinics and putative heterozygote
121 controls from gnomAD¹⁹, found 9,969 *KCNQ1* heterozygotes harboring 630 unique missense
122 and in-frame insertion/deletion variants. Plotting the observed penetrance of each variant by
123 residue recapitulated known associations with 'hot spot' regions of the protein; plotting our
124 structural penetrance density metric²⁰ (residue weighted by penetrance of adjacent residues in
125 3D environment) by residue resulted in more continuous estimates (Supplemental Figure 1).

126

127 We evaluated the functional, *in silico*, and structural features against the estimated LQT1
128 penetrance (the observed penetrance modestly biased towards the mean, called the empirical
129 posterior, see Materials and Methods) using Spearman-rank order coefficients, weighted
130 towards variants with many clinical observations (Figure 2 and Supplemental Table 1). We
131 found many channel biophysical properties were statistically significant (nominal $p < 0.05$). For
132 example, reductions in peak current decrease repolarization and, as the primary molecular
133 correlate of LQT1, predict higher LQT1 penetrance (Figure 2; Spearman correlation coefficient -
134 0.55 homozygous, -0.54 heterozygous). CardioBoost²¹ had the highest correlation coefficient
135 (+0.64) of the *in silico* predictors, followed by REVEL²² (+0.64) and Provean²³ (-0.61). The
136 structural LQT1-dist covariate had a Spearman correlation coefficient of +0.54. Integrating the
137 most relevant features using our previously described method¹⁷, we derived a LQT1 Bayesian
138 prior with a coefficient of +0.71 (10-fold cross validated Spearman correlation coefficient +0.65 –
139 see Materials and Methods). We additionally evaluated model covariates using Brier scores²⁴, a
140 probabilistic forecasting metric where 0 is most favorable, and 1 is least favorable (Table 1). We

141 observe Brier scores for the LQT1-dist metric of 0.062 while the *in silico* covariates CardioBoost
142 (0.19), REVEL (0.17), and PolyPhen2 (0.22) performed less well. The Brier score for the
143 Bayesian prior was 0.028 (10-fold cross validated Brier score 0.033) and 0.011 for the Bayesian
144 posterior.

145

146 A central advantage of our Bayesian penetrance estimate is the quantification of uncertainty
147 (Supplemental Figure 2 – see Materials and Methods)¹⁷. This is expressed as a hypothetical
148 number of heterozygotes, e.g., 7 of 10 clinically phenotyped individuals with a phenotype has a
149 greater uncertainty than 700 of 1,000 clinically phenotyped heterozygotes with a phenotype,
150 though the estimated penetrance is the same. To arrive at this number, we empirically test a
151 tuning parameter, equivalent to the number of hypothetically phenotyped heterozygotes, such
152 that 95% of the true observations (per variant empirical posterior) are contained within the EM
153 posterior's 95% credible interval across the distribution from 0 to 1.0 using boot strap sampling
154 (Supplemental Figure 2 – see outcomes with several tuning parameters tested). From this
155 analysis, for *KCNQ1-LQT1*, we suggest the Bayesian prior is empirically equivalent to the
156 information contained in approximately 10 clinically phenotyped individuals.

157

158 In Figure 3, we provide a representative example of the prior and posterior penetrance
159 estimates obtained by our approach imposed on the latter part of the S6 transmembrane
160 segment into the C-terminus (residues 350-400). The forest plot shows prior (green, blue, and
161 red) and posterior (black) estimates and their corresponding 95% credible intervals for variants
162 harbored by at least five heterozygotes. The 95% credible interval of the Bayesian prior
163 estimate is narrowed after the application of the likelihood (heterozygote status). For example,
164 for the variant p.Ala370Val, there is a moderate Bayesian prior probability (0.28). After applying
165 the clinical likelihood (1 affected heterozygote of 45 observed heterozygotes), the Bayesian
166 posterior is decreased (.067) along with the respective 95% credible interval. This method

167 provides a best probability estimate for these variants, which intrinsically accounts for
168 incomplete penetrance, even among high-penetrance variants.

169
170 *LQT3 Penetrance.* We performed a similar analysis for the *SCN5A*-LQT3 genotype-phenotype
171 pair. In contrast to LQT1, the LQT3 phenotype arises from a specific loss of channel
172 inactivation, which may arise through late current, window current, or altered kinetics of
173 inactivation²⁵. We previously curated a dataset to evaluate this relationship empirically¹⁸, which
174 includes a total of 86,118 *SCN5A* heterozygotes with 1,243 manifesting the LQT3 phenotype.
175 Analogous to LQT1, we updated prior penetrance estimates based on functional, structural, and
176 *in silico* features with this clinical evidence. The posterior estimates were empirically shown to
177 be equivalent to the information contained in 5 clinical observations of heterozygotes using the
178 same framework described above (Supplemental Figure 3).

179
180 *Bayesian Estimates Reflects Gene-specific Penetrance Among Channelopathies.* To assess
181 differences in penetrance among the four channelopathies (LQT1-3 and BrS), we compared the
182 Bayesian posterior penetrance estimate distributions for each gene-disease pair (Figure 4).
183 Observed penetrance (strictly frequentist) tends towards 0 or 1 owing to most unique variants
184 being observed in a single or few phenotyped heterozygotes (Figure 4A). The Bayesian
185 posterior penetrance estimates are distributed over a continuous bimodal distribution (Figure
186 4B). We observe a cluster of variants with low penetrance estimates, followed by a second
187 cluster with higher estimates which may loosely map onto the categorical ACMG framework. We
188 interpret these estimates as indicating ‘benign’ at low estimated penetrance, followed by a
189 continuous gradation of ‘risk allele’ to ‘pathogenic low penetrance’ to ‘pathogenic’ variants.
190 Formalizing these estimates as continuous disease-presentation probabilities explicitly accounts
191 for incomplete penetrance along this continuum. *SCN5A* variants associated with BrS and LQT3
192 do not display the same extent of bimodal distribution as those in *KCNQ1* and feature

193 comparatively more variants predicted to have very low penetrance (Figure 4C and 4D). This
194 finding partially reflects the composition of *SCN5A*, at approximately four times the size of
195 *KCNQ1* with large linkers (400 residues) between membrane spanning segments largely
196 uninvolved in channel function and correspondingly low estimated penetrance. Finally, *KCNH2*
197 variants also have a bimodal distribution like those for *KCNQ1* variants, but with a smaller
198 fraction predicted at high penetrance (Figure 4E). These observations also reflect the relative
199 fraction of functionally relevant residues within the gene. These differences are quantified in
200 Figure 4F. These distributions indicate half of identified *KCNQ1* variants have a penetrance
201 estimate of at least 0.41, suggesting a randomly chosen *KCNQ1* variant has a 50% chance of
202 producing a LQT1 penetrance greater than 41%. The probability distributions skew comparably
203 lower for *KCNH2*-LQT2 and *SCN5A*-LQT3 where half of observed variants have penetrance
204 estimates lower than 0.157 and 0.063, respectively.

205
206 *Distribution of Posterior Estimates within Individual ClinVar Annotations.* We next investigated
207 how our Bayesian estimates and observed penetrance compared with ClinVar categorical
208 designations. In Figure 5A, we present posterior estimates for Benign/Likely Benign (B/LB) and
209 Pathogenic/Likely Pathogenic (P/LP) variants for *KCNQ1*. Plotting the observed penetrance vs
210 category reveals that many variants are incompletely penetrant (Figure 5A). We observe that
211 the Bayesian estimates for B/LB cluster close to 0, although we show remarkable heterogeneity
212 for estimates of the P/LP variants (ranging from 0.17-0.90). We repeated this analysis for
213 variants within *KCNH2* (Figures 5C and 5D). We again observe distributions of Bayesian
214 penetrance estimates (0.093-0.95) as well as a high degree of incomplete penetrance among
215 P/LP variants. Some P/LP variants have been observed in relatively few individuals without a
216 phenotype, and therefore have an observed penetrance of 0 (Figure 5A/C). Further investigation
217 revealed that several of these variants have a P/LP ClinVar annotation which includes private

218 communications about heterozygote clinical phenotypes (such as *KCNH2* p.Gly657Ser), which
219 were therefore unavailable to incorporate into our model.

220
221 *Structural Implications of Variable Penetrance.* We mapped posterior penetrance estimates onto
222 Cryo-EM structures (PDBIDs 5VMS, 5VA1, and 5X0M for KCNQ1, KCNH2, and SCN5A
223 [homology modeled to include the c-terminal EF hand domain], respectively) of each protein and
224 interrogated global and ‘hot spot’ penetrance heterogeneity. As shown in Figure 6A, there is
225 substantial heterogeneity in penetrance across traditionally labelled ‘hot spot’ regions in Kv7.1,
226 including the pore domain, voltage sensing domains, and subunit assembly domains (Figure 6A
227 and 6B)²⁶. Whereas several variants in these ‘hot spot’ domains are observed to have high
228 posterior estimates, as indicated by the color and thickness of the putty rendering, there remain
229 several residues with comparatively low penetrance within the same domain. Interestingly, we
230 observe enriched penetrance across the known binding site of calmodulin (Figure 6C)²⁷. For
231 example, surface residues on two helices in contact with calmodulin both have high penetrance
232 estimates, including p.Trp379 (3 observed variants, 4 of 5 heterozygotes affected) and
233 p.Met520Arg (4 of 4 heterozygotes affected). Structural comparisons revealed that the Kv7.1
234 S5-S6 domain have higher penetrance estimates than those of Kv11.1. We observe that the
235 high pathogenicity of variants in the S5 helix continues into the S6 helix of Kv7.1 (p.Ala344Val,
236 17 of 20 heterozygotes affected; p.Gly345Arg, 2 of 2 heterozygotes affected; p.Leu353Pro, 8/8
237 heterozygotes affected), whereas those for Kv11.1 rapidly taper (residue p.Met645 – 4 unique
238 variants – 9/10 heterozygotes affected; p.Ser660Leu, 2/7 heterozygotes affected). This finding
239 is consistent with a recent report implicating variants in the Kv7.1 S6 domain as particularly
240 pathogenic, causing a significant decrease in event-free survival²⁸. This may be structurally
241 rationalized by the greater sensitivity of flexible motifs within the Kv7.1 S6 helix including the
242 ‘GSG’ motif²⁹ (p.Ser349Trp, 2 of 2 heterozygotes affected, and p.Gly350, 3 variants, 9 of 9
243 heterozygotes affected).

244

245 We next mapped Bayesian posteriors for BrS and LQT3 onto the structure of *SCN5A* (Figure 7A
246 and 7B). The BrS posterior estimates were highest in the pore region, especially near the
247 selectivity filter, with some additionally high penetrance variants in the voltage sensing domains
248 (VSDs) and the C-terminal EF-hand domain; however, even in the highly conserved pore
249 helices, there were several BrS low-penetrance residues. These results contrast with
250 penetrance estimates for LQT3, where high penetrance residues were concentrated in and near
251 the inactivation gate on the intracellular side of the channel. While some domains are
252 associated with both phenotypes (such as the C-terminal EF-hand domain), other regions of
253 $Na_v1.5$ are exclusively linked to BrS or LQT3 (VSD and pore for BrS and inactivation gate for
254 LQT3). For example, of the 164 heterozygotes for the variant p.Glu1784Lys, we observed 31
255 with BrS and 114 with LQT3 (posterior estimates 0.19 and 0.69, respectively). This variant is in
256 the C-terminus of the S6 helix, and recent structural studies have implicated its role in fast
257 inactivation³⁰. In contrast, the in-frame deletion p.Gln1507-1509del in the domain III-domain IV
258 linker (inactivation-gate) was LQT3 specific (85 of 87 heterozygotes LQT3 affected, 0 BrS). Our
259 highest BrS posterior estimate was for the variant p.Arg878Cys (32 of 36 heterozygotes
260 affected) in the domain II pore.

261

262

263 Discussion

264 *Bayesian Penetrance Estimates for Mendelian Arrhythmias.* We applied a probabilistic model to
265 generate prior and posterior penetrance estimates for the *KCNQ1-LQT1* and *SCN5A-LQT3*
266 genotype-phenotype pairs that explicitly account for incomplete penetrance in the model
267 framework. Functional, *in silico*, and structural features of these channels were significantly
268 associated with LQT1 and LQT3 penetrance. We found that these models carried information
269 equivalent to 10 and 5 heterozygote clinical observations, respectively. The *KCNQ1-LQT1*
270 model had a Bayesian prior 10-fold cross-validated Brier scores of 0.032, indicating excellent
271 probabilistic forecasting. We then analyzed the distributions of penetrance estimates for four
272 genotype-phenotype pairs and found *KCNQ1-LQT1* had the largest fraction of variants with high
273 estimated penetrance (Figure 5E). These continuous estimates were then mapped onto each
274 protein structure, which revealed a structural basis of these findings as well as significant
275 heterogeneity in traditionally annotated 'hot spot' domains. We curated these data and host
276 them in a convenient format for research and prospective clinical management.

277

278 *Variable Penetrance Among Genotype-Phenotype Pairs.* Incomplete penetrance is observed
279 even among highly deleterious variants. For example, the *KCNQ1* variant p.Ala341Val has
280 sharply decreased event-free survival compared to other *KCNQ1* missense variants²⁸, but still
281 provokes the phenotype incompletely (301 of 375 heterozygotes manifest LQT1). Extended to
282 all variants observed in at least one heterozygote, Figure 4 shows penetrance estimates for
283 relatively few variants exhibit >90% penetrance (quantified in Figure 4E) and a bimodal
284 distribution for LQT1 and LQT2 penetrance, a loosely bimodal distribution for BrS, and a taper
285 for LQT3. The fraction of significantly high penetrance variants is consistent with the fraction of
286 LQTS cases attributed to variants in these genes: roughly 50% of LQTS cases are attributable

287 to variants in *KCNQ1*, 40% in *KCNH2* and 10% in *SCN5A*³¹. This trend inversely correlates with
288 gene size: (K_v7.1 676 amino acids, K_v11.1 1159 amino acids, and Nav1.5 2016 amino acids).
289 For BrS and LQT3, more variants can confer loss-of-function for BrS, compared to the more
290 limited set of possible variants that could induce a 'gain-of-function' phenotype associated with
291 LQT3. This difference may explain the relative decrease in precision of the *SCN5A*-LQT3
292 estimates reflected in the lower number of phenotype observations compared to *KCNQ1*-LQT1
293 (5 vs 10). The predictive features are comparatively weaker due to the bias to estimate loss-of-
294 function rather than gain-of-function as a single score. Compared to LQT1 and LQT2, BrS (also
295 associated with loss-of-function) penetrance distribution has a lower fraction of variants with
296 penetrance >0.5, likely due to contributions to the phenotype from other genes or polygenic
297 modifiers (Figure 5E). This is consistent with recent suggestions of the oligogenic nature of BrS
298 as compared to more strictly Mendelian LQT1-3 with polygenic modifiers³². The complication of
299 both arrhythmia-associated gain-of-function and loss-of-function phenotypes for missense
300 variants in *SCN5A* likely contributes to the worse correlation between *SCN5A* predictive
301 features and LQT3 penetrance leading to lower hypothetical heterozygote count for *SCN5A*-
302 LQT3.

303

304 *Continuous Bayesian Penetrance Provides Higher Resolution Variant Interpretation.* The ACMG
305 variant classification scheme is a clinically useful categorical framework to interpret variants⁴.
306 While this approach enables convenient approximations for clinical decision making, variants
307 within each of these categories may nevertheless exert divergent risk due to incomplete
308 penetrance. The *KCNQ1* variant p.Val254Met has not been observed in gnomAD and is
309 associated with a high frequency of sudden cardiac death and syncope in Japanese
310 heterozygotes³³. From variant-specific features alone, we obtained a penetrance estimate of
311 0.65 and a posterior LQT1 penetrance estimate of 0.84. In contrast, the disease-associated

312 variant p.Gly589Asp has a higher allele-frequency ($4.96e-5$ in gnomAD) than expected for a
313 highly pathogenic variant ($2.5e-5$ rare allele cutoff³⁴), despite being annotated as Pathogenic in
314 ClinVar⁵. Accordingly, our model predicted a prior penetrance estimate of 0.37, and a posterior
315 estimate of 0.23 after incorporating clinical data (8 of 40 affected heterozygotes). Such a variant
316 clearly carries risk above the baseline population rate, but not as high as that conferred by
317 p.Val254Met. A strength of our approach is therefore the ability to capture this granular level of
318 detail, whereas classification methods lose this nuance. Our continuous estimates suggest that
319 certain variants may be considered ‘modifiers’ or exert subtle impact, consistent with the
320 terminology of “LQT-lite” proposed by Ackerman and colleagues³⁵⁻³⁷. This idea is additionally
321 consistent with recent work showing variable environment interactions in the presence of
322 common *SCN5A* variants, where the variant may act as a ‘modifier’ of penetrance³⁸.

323

324 The divergence of our approach, leveraging information contained within the variant-specific
325 features, can also be appreciated when contrasted with ClinVar categorical descriptions (Figure
326 5). ClinVar annotated P/LP variants display a range of predicted penetrance estimates (0.167-
327 0.903 *KCNQ1* and 0.0930-0.945 *KCNH2*); the effect is also evident from non-Bayesian
328 penetrance observations (Figure 5A and 5C). Furthermore, our findings in Figure 4A show that
329 observed penetrance is not sufficient for forecasting penetrance, that most unique variants are
330 observed in very few people leading to too many LQTS penetrance estimates of 0 or 1. Variant-
331 specific features modify these crude estimates from low numbers of phenotyped variants to shift
332 estimates away from the extremes to more intuitive and biologically reasonable estimates
333 (Figure 4B). Collectively, these observations support the notion that our continuous Bayesian
334 estimates offer a higher resolution alternative to categorical classification.

335

336 *Penetrance Heterogeneity within Structured Functional Domains.* Previous works have
337 implicated 'hot spot' regions within the three protein products based on collapsing of variants in
338 cases and controls; however, many of these studies preceded recent large-scale population
339 genome sequencing efforts^{26,39}. Our combination of genetic and structural data shows variable
340 penetrance throughout many traditional 'hot spot' domains (Figure 6 and 7). For example, not all
341 residues in the *SCN5A* domain IV VSD or pore are associated with high BrS penetrance (Figure
342 6A). These differences are further rationalized between the *SCN5A*-BrS and *SCN5A*-LQT3
343 pairs, where different electrophysiological parameters correspond to discrete structural features.
344 Even for higher penetrance variants within 'hot spots', many provoke the phenotype
345 incompletely. In *KCNH2*, the ClinVar Pathogenic variant p.Val822Met is located in the pore
346 domain 'hot spot' but affects only 27 of 42 heterozygotes with a Bayesian penetrance estimate
347 of 0.65. We also observe heterogeneity between homologous S6 segments in *Kv7.1* and
348 *Kv11.1*, with a much higher LQTS penetrance throughout the helix in the former. These results
349 highlight important structural differences in these proteins that contribute to clinical penetrance,
350 despite similar channel characteristics (both being voltage-gated potassium channels).
351 Altogether, these data suggest using variant location in 'hot spot' domains in ACMG variant
352 classifications may be premature⁴⁰. For instance, recent work from our lab performed a Deep
353 Mutational Scan of a 'hot spot' exon in *KCNH2*, and found experimentally that only 42% of all
354 possible amino acid substitutions substantially decreased trafficking⁴¹. We view the current
355 approach as providing higher resolution interpretation in these domains – this work provides
356 more information than categorical classification, or yes/no 'hot spot' annotations.

357

358 Mapping penetrance to structure also provides unique insights into the underlying channel
359 biology. For example, *Kv7.1* residues 364-383 and 510-533 form the A and B helices,
360 respectively, with several high-penetrance sites, including non-buried residues which interact

361 with calmodulin (Figure 6C). Calmodulin is global calcium sensor within the cardiomyocyte and
362 is important for regulating excitation-contraction coupling⁴². The functional implications of
363 Calmodulin binding $K_v7.1$ are speculative, however, a recent study implicated calmodulin as a
364 state-dependent switch to modulate channel gating⁴³. Our study suggests a high LQT1
365 penetrance when these interactions are abrogated by genetic variation, likely being mediated
366 through this loss of gating modulation. These results provide a complementary set of data to
367 implicate loss of the Calmodulin- $K_v7.1$ signaling axis as an etiology for LQT1.

368
369 *Comparison with Other Approaches.* Recent studies in the cardiac space have leveraged
370 machine learning to facilitate variant reclassification^{15,16}. Approaches such as GENESIS¹⁶ and
371 MLb-LDLr¹⁵ make progress towards this goal but rely on ClinVar data as a critical input. The
372 approach we take relies on classic regression strategies and expectation-maximization to
373 integrate data, and instead draws on all available variant-specific features to output a
374 *continuous* penetrance estimate calibrated to curated, granular clinical data. Rather than
375 focusing on classification, other interesting approaches have instead focused primarily on
376 functional impact, such as prediction of functional properties in the presence of missense
377 variants^{44,45}. The use of granular clinical data, each heterozygote evaluated as above or below a
378 clinically meaningful threshold represents an advance by which we can assert not only a
379 penetrance estimate, but also the uncertainty of the estimate – an approach well-tailored to
380 incompletely penetrant BrS and LQTS variants.

381
382 *Precision Medicine Applications.* An increasingly important goal of precision medicine is to
383 enable ‘genetics first approaches’, wherein sequencing of unascertained clinical cohorts may
384 prioritize individuals for tailored follow-up^{46,47}; however, prioritizing variant heterozygotes for
385 follow up remains difficult. Additionally, sequencing of large population cohorts has revealed an

386 unexpectedly large frequency of missense variants in genes associated with Mendelian
387 disease^{19,48,49}. It is unlikely there will ever be sufficient discovered heterozygotes for clinical
388 phenotyping to adjudicate the clinical consequence of all possible single nucleotide variants in
389 Mendelian disease genes⁵⁰. It is therefore imperative to maximally leverage all variant-specific
390 features to help facilitate an understanding of clinical consequence⁵¹. As many phenotypes
391 demonstrate variable penetrance, our method provides an initial gestalt from variant-specific
392 features which help tailor prospective precision medicine in concert with other clinical
393 observations. To calibrate the strength of these features, we provide an empirical equivalent of
394 heterozygote observations, an interpretable form of these data. Based on this progress, we
395 envision a future in which genetic testing forms a pre-test probability of disease which is
396 updated by clinical phenotyping. This schematic would represent an inversion of the current use
397 of genetics in medical practice, in which a genetic test most commonly modifies a clinical pre-
398 test probability.

399
400 *Limitations.* One limitation of our study is the ascertainment bias of highly penetrant variants in
401 clinical practice. Many asymptomatic heterozygotes will not be clinically phenotyped or
402 adequately sampled in current population sequencing studies. This bias is additionally reflected
403 in the availability of functional data, as most studies have interrogated variants with a high
404 suspicion of pathogenicity; however, this bias is increasingly tempered by functional evaluation
405 of less unascertained variants such as those in a recent study of arrhythmia genes in the
406 eMERGE network⁵². We are currently unable to satisfactorily account for variant combinations
407 such as compound heterozygotes⁵³. Data availability remains a limitation for model construction,
408 as several ClinVar annotations were based off 'personal communications' which resulted in low
409 or zero observed penetrance among P/LP variants in select cases.

410

411 **Conclusion**

412 Incomplete penetrance demands nuance to variant interpretation for the realization of genome-
413 first precision medicine approaches⁴⁶. We make progress towards this goal by elaborating a
414 probabilistic approach that considers each variant as having a continuous penetrance
415 probability and provides higher resolution in 'hot spot' domains to facilitate prospective clinical
416 management. This approach provides more information than classification and explicitly treats
417 incomplete penetrance in model construction. We render variant-specific features as
418 equivalents to clinically-phenotyped heterozygotes to democratize these data to a broader
419 audience without electrophysiology and structural biology expertise.

420

421 **Description of Supplemental Data**

422 We have included all referenced supplemental figures and tables (Supplemental Figures 1-3
423 and Supplemental Table 1), as well as a detailed description of the penetrance estimation
424 protocol in the Supplemental Methods section.

425 **Declaration of Interests**

426 The authors declare no competing interests.

427 **Ethics Declaration**

428 Institutional Review Board (#191563) of Vanderbilt University Medical Center granted a waiver
429 for this work based on 45 CFR 46.104 (d) category (4) for Exempt Review.

430 **Acknowledgements**

431 This research was funded by American Heart Association 907581 (MJO), a Marie Skłodowska-
432 Curie Individual Fellowship (H2020-MSCA-IF-2017; Grant Agreement No. 795209, LS), a
433 Fondazione CARIPLO, “Biomedical Research Conducted by Young Researchers” (Grant No.
434 2019-1691, LS), NIH R01HL160863 (BMR), American Heart Association 848898, Leducq
435 Foundation for Cardiovascular Research grant 18CVD05 (LC, JES, PJS, BMR), and partially
436 supported by the Italian Ministry of Health (LS, LC, FD, MCK, CS, PJS). Also, we are grateful to
437 Drs. Silvia Castelletti and Sabrina Bedogni for their help in the initial data collection.

438 **Web Resources**

439 OMIM, <http://www.omim.org/>

440 RCSB Protein Data Bank, <http://www.rcsb.org/pdb/home/home.do/>

441 Variant Browser, <https://variantbrowser.org/>

442 **Data and Code Availability**


443 All code used to generate the results are available at <https://github.com/kroncke-lab>.

444 **Author Contributions**

445 Conceptualization: MJO, BMK; Data curation: MJO, LS, ID, YW, KK, LC, FD, MCK, CS, AL, JES,
446 AK, SO, MH, FE, PJS, BMK; Formal Analysis: MJO, LS, ID, YW, KK, RT, DMR, MH, FE, PSJ,
447 BMK; Supervision: BMK; Visualization: MJO, BMK; Writing-original draft: MJO, BMK; Writing-
448 review & editing: MJO, LS, ID, YW, KK, LC, MCK, CS, AL, JES, AK, SO, RT, DMR, MH, FE, PJS,
449 BMK.

450

451




452

453

454 **Figure 1. Schematic of Bayesian approach**

455 An empirical prior is derived from the average penetrance and variance of all variants. We add
 456 variant specific counts to derive an empirical posterior for each variant. Within the context of an
 457 Expectation-Maximization model, we update the empirical posterior with variant specific
 458 features. This provides an updated prior, which is further iterated with clinical data and variant
 459 specific features until the penetrance does not continue to change. This outputs a Bayesian
 460 prior used in future analyses.

461



462


463

464 **Figure 2. LQT1 Bayesian Model Covariate Evaluation**

465 Weighted Spearman Rho correlations and 95% confidence intervals for each covariate against

466 LQT1 empirical penetrance.

467



468


469 Figure 3. LQT1 Penetrance Estimate Forest Plots and Structure

470 Depiction of prior and posterior penetrance estimates for residues 350-400 (S6 transmembrane
471 segment into the C-terminus) with >5 carriers. The prior penetrance estimates and 95% credible
472 interval are depicted in gold, with the posterior and updated 95% credible intervals in black.

473 Total number of observed heterozygotes are given. 95% credible interval changes proportionally
474 with the number of clinical observations.

475

476



477

478 **Figure 4. Histograms of Variant Penetrance in 4 Mendelian Channelopathies**

479 A) Observed penetrance frequencies for *KCNQ1*-LQT1 variants. Note bimodal distribution of
 480 penetrance frequencies in the observed penetrance.

481 B) Frequencies of Bayesian posterior penetrance estimates for *KCNQ1*-LQT1. Labels indicate
 482 clinical 'gestalts' for different ranges of penetrance fractions to map ACMG classifications.


483 C) Bayesian posterior frequencies for *SCN5A*-LQT3. This distribution has the lowest penetrance
484 estimates with few very highly penetrant variants.

485 D) Bayesian posterior frequencies for *SCN5A*-BrS. Covariates predict a more left-skewed
486 distribution with a mild bimodal distribution. The highest decile of observations has less
487 penetrance than those of LQT1 and LQT2.

488 E) Bayesian posterior frequencies for *KCNH2*-LQT2. Bimodal distribution of penetrance
489 frequencies.

490 F) Quantile table of distributions of posterior penetrance fractions for each genotype-phenotype
491 pair.

492



493

494 **Figure 5. Bayesian and Observed Penetrance Associated with ClinVar Annotations.**


495 A) Plotting the observed penetrance by ClinVar category shows that many *KCNQ1* P/LP
496 variants are incompletely penetrant.

497 B) Most ClinVar Benign and Likely Benign *KCNQ1* variants have low Bayesian penetrance
498 estimates. Notably, Pathogenic and Likely Pathogenic variants have a wide distribution of
499 Bayesian penetrance.

500 C) P/LP *KCNH2* variants have a wide distribution of Bayesian penetrance scores in our model.

501 D) Several ClinVar P/LP variants within *KCNH2* are incompletely penetrant.

502



503

504 **Figure 6. Structural Basis of *KCNQ1-LQT1* Penetrance and ‘Hot-Spot’ Domain**
505 **Heterogeneity**

506 A) Posterior penetrance estimates imposed upon the tetrameric experimental K_v7.1 structure.

507 The subassembly domain (SAB) and pore domain have a high degree of penetrance.

508 Calmodulin (CaM) binding domains and Voltage Sensing Domains (VSD) also exhibit high,

509 although heterogenous, penetrance.

510 B) View of channel embedded in membrane from extracellular perspective. We observe very

511 high penetrance in the channel pore and along VSD.

512 C) Close up of calmodulin binding domain with experimentally observed Calmodulin binding.

513 Residues with high contact show enlarged penetrance estimates.

514 D) K_v7.1 S5-S6 helices with nearly uniform high penetrance estimates. Example variants



515 provided.

516 E) K_v11.1 S5-S6 helices. Penetrance tapers along the S6 transmembrane domain compared to

517 that observed for K_v7.1.

518

519



520

521 **Figure 7. Structural heterogeneity of BrS and LQT3 penetrance**

522 A) Bayesian posterior estimates for *SCN5A*-BrS. High degree of penetrance along the channel
523 pore and voltage sensing domain (VSD).

524 B) Bayesian posterior estimates for *SCN5A*-LQT3. Fewer residues show high penetrance for
525 LQT3 compared to BrS, consistent with the molecular defects precipitating each disease. Some
526 overlap is observed in the C-terminal EF Hand domain, whereas variants in the pore are highly
527 tolerated compared to BrS.

528

529 **Table 1.** Brier Scores for KCNQ1-LQT1 Model.

Covariate	Brier Score
CardioBoost	0.19
Polyphen2	0.22
REVEL (unadjusted)	0.17
LQT1-Dist	0.062
Bayesian Prior	0.028
Bayesian Posterior	0.010

530

531

532 **References**

533

- 534 1 Wright, C. F. *et al.* Assessing the Pathogenicity, Penetrance, and Expressivity of Putative
535 Disease-Causing Variants in a Population Setting. *Am J Hum Genet* **104**, 275-286 (2019).
536 <https://doi.org/10.1016/j.ajhg.2018.12.015>
- 537 2 McClellan, J. & King, M. C. Genetic heterogeneity in human disease. *Cell* **141**, 210-217
538 (2010). <https://doi.org/10.1016/j.cell.2010.03.032>
- 539 3 Cooper, D. N., Krawczak, M., Polychronakos, C., Tyler-Smith, C. & Kehrer-Sawatzki, H.
540 Where genotype is not predictive of phenotype: towards an understanding of the
541 molecular basis of reduced penetrance in human inherited disease. *Hum Genet* **132**, 1077-
542 1130 (2013). <https://doi.org/10.1007/s00439-013-1331-2>
- 543 4 Richards, S. *et al.* Standards and guidelines for the interpretation of sequence variants: a
544 joint consensus recommendation of the American College of Medical Genetics and
545 Genomics and the Association for Molecular Pathology. *Genet Med* **17**, 405-424 (2015).
546 <https://doi.org/10.1038/gim.2015.30>
- 547 5 Landrum, M. J. *et al.* ClinVar: public archive of relationships among sequence variation
548 and human phenotype. *Nucleic Acids Res* **42**, D980-985 (2014).
549 <https://doi.org/10.1093/nar/gkt1113>
- 550 6 Schwartz, P. J. *et al.* Inherited cardiac arrhythmias. *Nat Rev Dis Primers* **6**, 58 (2020).
551 <https://doi.org/10.1038/s41572-020-0188-7>
- 552 7 Hosseini, S. M. *et al.* Reappraisal of Reported Genes for Sudden Arrhythmic Death:
553 Evidence-Based Evaluation of Gene Validity for Brugada Syndrome. *Circulation* **138**, 1195-
554 1205 (2018). <https://doi.org/10.1161/circulationaha.118.035070>
- 555 8 Adler, A. *et al.* An International, Multicentered, Evidence-Based Reappraisal of Genes
556 Reported to Cause Congenital Long QT Syndrome. *Circulation* **141**, 418-428 (2020).
557 <https://doi.org/10.1161/CIRCULATIONAHA.119.043132>
- 558 9 Priori, S. G., Napolitano, C. & Schwartz, P. J. Low penetrance in the long-QT syndrome:
559 clinical impact. *Circulation* **99**, 529-533 (1999). <https://doi.org/10.1161/01.cir.99.4.529>
- 560 10 Lahrouchi, N. *et al.* Transethnic Genome-Wide Association Study Provides Insights in the
561 Genetic Architecture and Heritability of Long QT Syndrome. *Circulation* **142**, 324-338
562 (2020). <https://doi.org/10.1161/circulationaha.120.045956>
- 563 11 Wijeyeratne, Y. D. *et al.* SCN5A Mutation Type and a Genetic Risk Score Associate Variably
564 With Brugada Syndrome Phenotype in SCN5A Families. *Circ Genom Precis Med* **13**,
565 e002911 (2020). <https://doi.org/10.1161/circgen.120.002911>
- 566 12 Nauffal, V. *et al.* Monogenic and Polygenic Contributions to QTc Prolongation in the
567 Population. *medRxiv*, 2021.2006.2018.21258578 (2021).
568 <https://doi.org/10.1101/2021.06.18.21258578>
- 569 13 van Rees, J. B. *et al.* Inappropriate implantable cardioverter-defibrillator shocks:
570 incidence, predictors, and impact on mortality. *J Am Coll Cardiol* **57**, 556-562 (2011).
571 <https://doi.org/10.1016/j.jacc.2010.06.059>

- 572 14 Schwartz, P. J. *et al.* Who are the long-QT syndrome patients who receive an implantable
573 cardioverter-defibrillator and what happens to them?: data from the European Long-QT
574 Syndrome Implantable Cardioverter-Defibrillator (LQTS ICD) Registry. *Circulation* **122**,
575 1272-1282 (2010). <https://doi.org/10.1161/circulationaha.110.950147>
- 576 15 Larrea-Sebal, A. *et al.* MLb-LDLr: A Machine Learning Model for Predicting the
577 Pathogenicity of LDLr Missense Variants. *JACC Basic Transl Sci* **6**, 815-827 (2021).
578 <https://doi.org/10.1016/j.jacbts.2021.08.009>
- 579 16 Draelos, R. L. *et al.* GENESIS: Gene-Specific Machine Learning Models for Variants of
580 Uncertain Significance Found in Catecholaminergic Polymorphic Ventricular Tachycardia
581 and Long QT Syndrome-Associated Genes. *Circ Arrhythm Electrophysiol*,
582 101161circep121010326 (2022). <https://doi.org/10.1161/circep.121.010326>
- 583 17 Kozek, K. *et al.* Estimating the Post-Test Probability of Long QT Syndrome Diagnosis for
584 Rare KCNH2 Variants. *Circ Genom Precis Med* (2021).
585 <https://doi.org/10.1161/circgen.120.003289>
- 586 18 Kroncke, B. M. *et al.* A Bayesian method to estimate variant-induced disease penetrance.
587 *PLoS Genet* **16**, e1008862 (2020). <https://doi.org/10.1371/journal.pgen.1008862>
- 588 19 Karczewski, K. J. *et al.* The mutational constraint spectrum quantified from variation in
589 141,456 humans. *Nature* **581**, 434-443 (2020). [https://doi.org/10.1038/s41586-020-](https://doi.org/10.1038/s41586-020-2308-7)
590 [2308-7](https://doi.org/10.1038/s41586-020-2308-7)
- 591 20 Kroncke, B. M. *et al.* Protein structure aids predicting functional perturbation of missense
592 variants in SCN5A and KCNQ1. *Comput Struct Biotechnol J* **17**, 206-214 (2019).
593 <https://doi.org/10.1016/j.csbj.2019.01.008>
- 594 21 Zhang, X. *et al.* Disease-specific variant pathogenicity prediction significantly improves
595 variant interpretation in inherited cardiac conditions. *Genet Med* **23**, 69-79 (2021).
596 <https://doi.org/10.1038/s41436-020-00972-3>
- 597 22 Ioannidis, N. M. *et al.* REVEL: An Ensemble Method for Predicting the Pathogenicity of
598 Rare Missense Variants. *Am J Hum Genet* **99**, 877-885 (2016).
599 <https://doi.org/10.1016/j.ajhg.2016.08.016>
- 600 23 Choi, Y. & Chan, A. P. PROVEAN web server: a tool to predict the functional effect of amino
601 acid substitutions and indels. *Bioinformatics* **31**, 2745-2747 (2015).
602 <https://doi.org/10.1093/bioinformatics/btv195>
- 603 24 BRIER, G. W. VERIFICATION OF FORECASTS EXPRESSED IN TERMS OF PROBABILITY.
604 *Monthly Weather Review* **78**, 1-3 (1950). [https://doi.org/10.1175/1520-](https://doi.org/10.1175/1520-0493(1950)078<0001:vofeit>2.0.co;2)
605 [0493\(1950\)078<0001:vofeit>2.0.co;2](https://doi.org/10.1175/1520-0493(1950)078<0001:vofeit>2.0.co;2)
- 606 25 Wilde, A. A. M. & Amin, A. S. Clinical Spectrum of SCN5A Mutations: Long QT Syndrome,
607 Brugada Syndrome, and Cardiomyopathy. *JACC Clin Electrophysiol* **4**, 569-579 (2018).
608 <https://doi.org/10.1016/j.jacep.2018.03.006>
- 609 26 Kapa, S. *et al.* Genetic testing for long-QT syndrome: distinguishing pathogenic mutations
610 from benign variants. *Circulation* **120**, 1752-1760 (2009).
611 <https://doi.org/10.1161/CIRCULATIONAHA.109.863076>
- 612 27 Sun, J. & MacKinnon, R. Cryo-EM Structure of a KCNQ1/CaM Complex Reveals Insights
613 into Congenital Long QT Syndrome. *Cell* **169**, 1042-1050.e1049 (2017).
614 <https://doi.org/10.1016/j.cell.2017.05.019>

- 615 28 Schwartz, P. J. *et al.* Mutation location and IKs regulation in the arrhythmic risk of long QT
616 syndrome type 1: the importance of the KCNQ1 S6 region. *Eur Heart J* **42**, 4743-4755
617 (2021). <https://doi.org/10.1093/eurheartj/ehab582>
- 618 29 Sun, J. & MacKinnon, R. Structural Basis of Human KCNQ1 Modulation and Gating. *Cell*
619 **180**, 340-347.e349 (2020). <https://doi.org/10.1016/j.cell.2019.12.003>
- 620 30 Li, Z. *et al.* Structure of human Na(v)1.5 reveals the fast inactivation-related segments as
621 a mutational hotspot for the long QT syndrome. *Proc Natl Acad Sci U S A* **118** (2021).
622 <https://doi.org/10.1073/pnas.2100069118>
- 623 31 Napolitano, C. *et al.* Genetic testing in the long QT syndrome: development and validation
624 of an efficient approach to genotyping in clinical practice. *Jama* **294**, 2975-2980 (2005).
625 <https://doi.org/10.1001/jama.294.23.2975>
- 626 32 Barc, J. *et al.* Genome-wide association analyses identify new Brugada syndrome risk loci
627 and highlight a new mechanism of sodium channel regulation in disease susceptibility.
628 *Nat Genet* **54**, 232-239 (2022). <https://doi.org/10.1038/s41588-021-01007-6>
- 629 33 Yagi, N. *et al.* A challenge for mutation specific risk stratification in long QT syndrome type
630 1. *J Cardiol* **72**, 56-65 (2018). <https://doi.org/10.1016/j.jjcc.2017.12.011>
- 631 34 Whiffin, N. *et al.* Using high-resolution variant frequencies to empower clinical genome
632 interpretation. *Genet Med* **19**, 1151-1158 (2017). <https://doi.org/10.1038/gim.2017.26>
- 633 35 Lane, C. M. *et al.* Long QT syndrome type 5-Lite: Defining the clinical phenotype
634 associated with the potentially proarrhythmic p.Asp85Asn-KCNE1 common genetic
635 variant. *Heart Rhythm* **15**, 1223-1230 (2018).
636 <https://doi.org/10.1016/j.hrthm.2018.03.038>
- 637 36 Giudicessi, J. R., Roden, D. M., Wilde, A. A. M. & Ackerman, M. J. Classification and
638 Reporting of Potentially Proarrhythmic Common Genetic Variation in Long QT Syndrome
639 Genetic Testing. *Circulation* **137**, 619-630 (2018).
640 <https://doi.org/10.1161/circulationaha.117.030142>
- 641 37 Schwartz, P. J., Crotti, L. & George, A. L., Jr. Modifier genes for sudden cardiac death. *Eur*
642 *Heart J* **39**, 3925-3931 (2018). <https://doi.org/10.1093/eurheartj/ehy502>
- 643 38 Wada, Y. *et al.* Common Ancestry-specific Ion Channel Variants Predispose to Drug-
644 induced Arrhythmias. *Circulation* (2022).
645 <https://doi.org/10.1161/circulationaha.121.054883>
- 646 39 Kapplinger, J. D. *et al.* Spectrum and prevalence of mutations from the first 2,500
647 consecutive unrelated patients referred for the FAMILION long QT syndrome genetic test.
648 *Heart Rhythm* **6**, 1297-1303 (2009). <https://doi.org/10.1016/j.hrthm.2009.05.021>
- 649 40 Walsh, R. *et al.* Enhancing rare variant interpretation in inherited arrhythmias through
650 quantitative analysis of consortium disease cohorts and population controls. *Genet Med*
651 **23**, 47-58 (2021). <https://doi.org/10.1038/s41436-020-00946-5>
- 652 41 Ng, C. A. *et al.* A massively parallel assay accurately discriminates between functionally
653 normal and abnormal variants in a hotspot domain of KCNH2. *Am J Hum Genet* (2022).
654 <https://doi.org/10.1016/j.ajhg.2022.05.003>
- 655 42 Crotti, L. *et al.* Calmodulin mutations and life-threatening cardiac arrhythmias: insights
656 from the International Calmodulinopathy Registry. *Eur Heart J* **40**, 2964-2975 (2019).
657 <https://doi.org/10.1093/eurheartj/ehz311>

- 658 43 Kang, P. W. *et al.* Calmodulin acts as a state-dependent switch to control a cardiac
659 potassium channel opening. *Sci Adv* **6** (2020). <https://doi.org/10.1126/sciadv.abd6798>
- 660 44 Clerx, M., Heijman, J., Collins, P. & Volders, P. G. A. Predicting changes to I(Na) from
661 missense mutations in human SCN5A. *Sci Rep* **8**, 12797 (2018).
662 <https://doi.org/10.1038/s41598-018-30577-5>
- 663 45 Heyne, H. O. *et al.* Predicting functional effects of missense variants in voltage-gated
664 sodium and calcium channels. *Sci Transl Med* **12** (2020).
665 <https://doi.org/10.1126/scitranslmed.aay6848>
- 666 46 Parikh, V. N. Promise and Peril of Population Genomics for the Development of Genome-
667 First Approaches in Mendelian Cardiovascular Disease. *Circ Genom Precis Med* **14**,
668 e002964 (2021). <https://doi.org/10.1161/circgen.120.002964>
- 669 47 Gneccchi, M., Sala, L. & Schwartz, P. J. Precision Medicine and cardiac channelopathies:
670 when dreams meet reality. *Eur Heart J* **42**, 1661-1675 (2021).
671 <https://doi.org/10.1093/eurheartj/ehab007>
- 672 48 Backman, J. D. *et al.* Exome sequencing and analysis of 454,787 UK Biobank participants.
673 *Nature* **599**, 628-634 (2021). <https://doi.org/10.1038/s41586-021-04103-z>
- 674 49 Taliun, D. *et al.* Sequencing of 53,831 diverse genomes from the NHLBI TOPMed Program.
675 *Nature* **590**, 290-299 (2021). <https://doi.org/10.1038/s41586-021-03205-y>
- 676 50 Weile, J. & Roth, F. P. Multiplexed assays of variant effects contribute to a growing
677 genotype-phenotype atlas. *Hum Genet* **137**, 665-678 (2018).
678 <https://doi.org/10.1007/s00439-018-1916-x>
- 679 51 Hille, B. *Ion channels of excitable membranes*. 3rd edn, (Sinauer, 2001).
- 680 52 Glazer, A. M. *et al.* Arrhythmia Variant Associations and Reclassifications in the eMERGE-
681 III Sequencing Study. *Circulation* (2021).
682 <https://doi.org/10.1161/circulationaha.121.055562>
- 683 53 Renaux, A. *et al.* ORVAL: a novel platform for the prediction and exploration of disease-
684 causing oligogenic variant combinations. *Nucleic Acids Res* **47**, W93-w98 (2019).
685 <https://doi.org/10.1093/nar/gkz437>
686